Pharmaceuticals
What’s different (and not) about injecting GA drugs
Tips for injecting pegcetacoplan and avacincaptad pegol for geographic atrophy.
Update: Gene therapy clinical trials in neovascular age-related macular degeneration
Companies are attacking the disease from multiple angles.
How anti-VEGF biosimilars are changing retina care
Biosimilars are reducing costs and increasing access, but in retina they also face unique challenges compared with other medical specialties.
Pearls for the Port Delivery System with Ranibizumab refill-exchange procedure
This modality may help decrease the treatment burden.
Clinical primer on Eylea HD: Review of the current data
Here’s what we know about the new high-dose aflibercept based on the pivotal trials.
Hitting the century mark: 100 candidates and counting
Geographic atrophy continues to be the fastest-growing area of interest, and new entries double the number of dropouts.
The ocular side effects of emerging oncology meds
A review of how a variety of immunotherapy and targeted therapies for cancer can impact the retina and the rest of the eye.
Gene therapy delivery: Examining the evidence
A look at the benefits and drawbacks of the three dominant modalities in clinical trials.
Pipeline Report: New entries continue to exceed exits
Exits for discontinued programs (three over two years) exceed exits for approvals (two).
Uveitis risk of ICPIs for cancer
Immune checkpoint inhibitors are becoming more widely available, but they’ve been linked to uveitis in some patients.
Five things to know about biosimilars in retina
A primer on the review and approval processes as the first anti-VEGF biosimilar prepares for launch in 2022.
Using anti-VEGF agents in uveitis
A review of the available evidence and anecdotal reports supporting their use.
Five emerging treatments show mixed results
Uncertainty about PVL for VMT and aflibercept for NPDR, some clarity on PDT, and early promise for stem cells and a bioresorbable implant.
Taking treatment beyond adalimumab
An update on biologic alternatives for ocular inflammatory disease when the approved agent just won’t cut it.
Rethinking routine use of steroid drops after surgery
Why do we use postop drops the way we do? The case for subconjunctival triamcinolone.
20 milestones ahead in AMD, DME meds
A look at chemical and biologic agents queued this year or next for key steps toward commercialization.
AKB-9778 as an Adjunct to Anti-VEGF
A deeper dive into how this Tie-2 activator stabilizes the retinal vasculature.
10 Abstracts Worth a Second Look
A review of compelling presentations in retina from ARVO.
Current Issue
Continuing Medical Education
Additional Publications
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Sponsored by Regeneron
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
Eyepoint Yutiq: A Discussion Among Experts on the Treatment of Uveitis Affecting the Posterior Segment
